Yield10 Bioscience, Inc. (YTENQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Oct 27, 2025, 4:00 PM EDT
Yield10 Bioscience Revenue
Yield10 Bioscience had revenue of $450.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $750.00K, up 190.70% year-over-year. In the year 2023, Yield10 Bioscience had annual revenue of $60.00K, down -86.67%.
Revenue (ttm)
750.00K
Revenue Growth
+190.70%
P/S Ratio
0.00
Revenue / Employee
25.86K
Employees
29
Market Cap
73.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 60.00K | -390.00K | -86.67% |
| Dec 31, 2022 | 450.00K | -164.00K | -26.71% |
| Dec 31, 2021 | 614.00K | -185.00K | -23.15% |
| Dec 31, 2020 | 799.00K | -7.00K | -0.87% |
| Dec 31, 2019 | 806.00K | 250.00K | 44.96% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cardinal Ethanol, LLC | 350.34M |
| The Monarch Cement Company | 252.15M |
| Rubber Leaf | 2.02M |
| General Enterprise Ventures | 1.83M |
| Premier Development & Investment | 1.10M |
| Chykingyoung Investment Development Holdings | 305.65K |
| Panamera Holdings | 212.04K |
Yield10 Bioscience News
- 1 year ago - Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals - Accesswire
- 1 year ago - Yield10 Bioscience Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - GlobeNewsWire
- 1 year ago - Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina - GlobeNewsWire
- 1 year ago - Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label - GlobeNewsWire
- 1 year ago - Yield10 Bioscience Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Yield10 Bioscience Announces Delisting from Nasdaq - GlobeNewsWire
- 1 year ago - Yield10 Bioscience Announces 1-for-24 Reverse Stock Split - GlobeNewsWire